Connect

Connect

with a Cardinal Health representative

866.476.1340

Thank you for connecting with us.
*
 
 
   
Please fill out this field

Part B Billing For Biosimilar Products: Why the Modifier?

Since the 2010 passage of the Biologics Price Competition and Innovation Act, the FDA has worked to develop and implement an abbreviated licensure pathway for biological products proven to be interchangeable with a previously-licensed biological reference product.

Members Login

Become a member today